SCHEMBL30748948

SCHEMBL30748948

Clc1ncc(C2=CCCCO2)c(Nc2ccc(N3CCOCC3)nc2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 2/20 0.43
RAB9A P51151 1/20 0.42
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
CYP1A2 P05177 1/20 0.40
CNR2 P34972 3/20 0.40
JAK1 P23458 1/20 0.40
JAK3 P52333 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
PTK6 Q13882 1/20 0.39
FGFR2 P21802 1/20 0.39
FGFR3 P22607 1/20 0.39
DGAT1 O75907 2/20 0.38
PPARG P37231 1/20 0.38
PDGFRB P09619 1/20 0.38
SRC P12931 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749121 0.84 FLT3 (0.44) FLT3RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL31691299 0.80 GAA (0.38) FLT3MAPTCYP1A2JAK1JAK3
SCHEMBL30748886 0.78 MAPT (0.48) FLT3RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL30749035 0.71 MAPK14 (0.52) FLT3RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL2061358 0.68 MAPT (0.62) MAPTSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL21802045 0.67 FLT3 (0.81) FLT3
SCHEMBL30749026 0.65 GAA (0.40) FLT3RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL30749117 0.65 FLT3 (0.40) FLT3RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL4068527 0.65 FLT3 (0.56) FLT3RAB9AMAPTSMN1; SMN2LMNA
SCHEMBL2103715 0.65 SYK (0.75) FLT3MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT FLT3 2266/4885RAB9A 2172/4885MAPT 3029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.